CH.05 / COLOPHON
what this dossier is, and what it isn't
PT-141 MD is an independent editorial project. We do not employ clinicians and we do not provide medical advice. The name carries an editorial framing, not a clinical one.
What we are
PT-141 MD is an independent editorial project that publishes summaries of the peer-reviewed research literature on bremelanotide. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We are not affiliated with the compound's original developer, its current licensee, or any commercial seller of the approved product. Our work is editorial commentary on publicly available science.
The 'MD' in the name is editorial framing — a position the publisher occupies relative to the literature, in the same sense that a physician's-desk-reference monograph carries that register without being a prescription itself. It is not a claim that this site offers treatment, consultation, prescription, or any other clinical service. It does not.
Editorial standards and sourcing
Every quantitative claim on every page of this dossier cites a primary source. Sources are restricted to: peer-reviewed journal articles indexed in PubMed; FDA approval documents and product labeling; ClinicalTrials.gov registry entries; and NIH-maintained pharmacology databases (e.g., LiverTox). We do not cite secondary aggregators, encyclopedia summaries, podcasts, or unattributed commentary.
Where the evidence base is preclinical, we say so. Where the evidence base is from a specific trial population — premenopausal women with acquired generalized HSDD, for the RECONNECT program — we name that population rather than generalizing. Where a finding is contested in the literature (the RECONNECT satisfying-sexual-events endpoint, for instance), we describe both sides.
We do not use brand names. All compounds are referred to by their INN or USAN. We do not write recommendations, dose suggestions, or 'considerations' for any individual patient — those decisions belong between the patient and a prescribing clinician.
What we will not do
We will not invent a clinician. There is no 'Dr. So-and-so' here. We will not claim a physical address, a phone number, or a clinic location. We will not refer to 'our doctors,' 'our pharmacists,' or 'our clinical team' — we have none of those.
We will not recommend, sell, broker, or facilitate the purchase of any product. We will not advise on dosing for any individual patient. We will not promote off-label use of any compound. We will not pretend the limits of the FDA-approved indication do not exist, and we will not pretend the open questions in the literature have been resolved when they have not.
The disclaimer in plain language
Nothing on this site is medical advice. Nothing on this site is a recommendation to take, purchase, or self-administer any drug. Bremelanotide is an FDA-approved prescription pharmaceutical for a narrow indication; any decision about its use is between the patient and a qualified clinician. Research-grade compound distributed outside the approved subcutaneous autoinjector product is not pharmacy-grade material and is not approved for human self-administration.
If you spot an error in a citation, a misreading of a study, or a claim that lacks a source, write to us. We correct in place and we keep a change log.